Balyasny Asset Management
BOLD

Balyasny Asset Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Balyasny Asset Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-79,193
Closed -$4.74M – 1687
2019
Q4 		$4.74M Buy
+79,193
New +$2.97M 0.03% 598
2019
Q2 		– Sell
-22,277
Closed -$869K – 1840
2019
Q1 		$869K Sell
22,277
-117,579
-84% -$3.37M 0.01% 1058
2018
Q4 		$2.98M Buy
139,856
+72,312
+107% +$1.87M 0.02% 617
2018
Q3 		$2.67M Buy
67,544
+30,760
+84% +$1.15M 0.01% 899
2018
Q2 		$1.41M Sell
36,784
-395,332
-91% -$14.6M 0.01% 1047
2018
Q1 		$13M Buy
432,116
+395,866
+1,092% +$13.4M 0.05% 448
2017
Q4 		$1.13M Buy
+36,250
New +$995K ﹤0.01% 1304

Balyasny Asset Management's BOLD Position: Q1 2020 in Review

Balyasny Asset Management sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 79,193 shares — an estimated $4.74M sold.

Balyasny Asset Management first reported a position in BOLD in Q4 2017 and held it in 7 quarters. The position peaked at $13M in Q1 2018. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

  • Balyasny Asset Management reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
  • Balyasny Asset Management sold 79,193 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $4.74M.
  • Balyasny Asset Management first reported a position in Audentes Therapeutics, Inc in Q4 2017 and held it in 7 quarters.
  • Balyasny Asset Management's Audentes Therapeutics, Inc position peaked at $13M in Q1 2018.
  • 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Balyasny Asset Management's 13F filing for Q1 2020, filed 15 May 2020.